Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
Dow
AstraZeneca
Mallinckrodt

Last Updated: August 15, 2022

Investigational Drug Information for KHK7580


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for KHK7580?

KHK7580 is an investigational drug.

There have been 9 clinical trials for KHK7580. The most recent clinical trial was a Phase 3 trial, which was initiated on September 29th 2015.

The most common disease conditions in clinical trials are Hyperparathyroidism, Hyperparathyroidism, Secondary, and Neoplasm Metastasis. The leading clinical trial sponsors are Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd, and Kyowa Hakko Kirin Company, Limited.

There are four US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for KHK7580
TitleSponsorPhase
Pharmacokinetic Study of KHK7580 in Healthy Adult VolunteersKyowa Hakko Kirin China Pharmaceutical Co., LTD.Phase 1
Pharmacokinetic Study of KHK7580 in Healthy Adult VolunteersKyowa Kirin Co., Ltd.Phase 1
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in AsiaKyowa Hakko Kirin China Pharmaceutical Co., LTD.Phase 3

See all KHK7580 clinical trials

Clinical Trial Summary for KHK7580

Top disease conditions for KHK7580
Top clinical trial sponsors for KHK7580

See all KHK7580 clinical trials

US Patents for KHK7580

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
KHK7580 See Plans and Pricing Pharmaceutical composition containing an arylalkylamine compound KYOWA HAKKO KIRIN CO., LTD. (Chiyoda-ku, JP) See Plans and Pricing
KHK7580 See Plans and Pricing Arylalkylamine compound and process for preparing the same Mitsubishi Tanabe Pharma Corporation (Osaka-Shi, JP) See Plans and Pricing
KHK7580 See Plans and Pricing Arylalkylamine compound and process for preparing the same Mitsubishi Tanabe Pharma Corporation (Osaka, JP) See Plans and Pricing
KHK7580 See Plans and Pricing Crystalline 4-(3S-(1R-(1-napthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid MITSUBISHI TANABE PHARMA CORPORATION (Osaka, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for KHK7580

Drugname Country Document Number Estimated Expiration Related US Patent
KHK7580 China CN108135883 2035-10-07 See Plans and Pricing
KHK7580 European Patent Office EP3360551 2035-10-07 See Plans and Pricing
KHK7580 Japan JP2017071599 2035-10-07 See Plans and Pricing
KHK7580 Japan JP2017071605 2035-10-07 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
Dow
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.